These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1975883)

  • 1. Debrisoquine hydroxylation phenotyping: do we expect too much?
    Mitchell SC; Haley CS
    Lancet; 1990 Sep; 336(8716):694. PubMed ID: 1975883
    [No Abstract]   [Full Text] [Related]  

  • 2. Diurnal effects on debrisoquine hydroxylation phenotyping.
    Lee EJ
    Eur J Clin Pharmacol; 1988; 35(4):441-2. PubMed ID: 3197754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphism of debrisoquine hydroxylation among Finns and Lapps.
    Arvela P; Kirjarinta M; Kirjarinta M; Kärki N; Pelkonen O
    Br J Clin Pharmacol; 1988 Nov; 26(5):601-3. PubMed ID: 3207564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methoxyphenamine and dextromethorphan as safe probes for debrisoquine hydroxylation polymorphism.
    Roy SD; Hawes EM; Hubbard JW; McKay G; Midha KK
    Lancet; 1984 Dec; 2(8416):1393. PubMed ID: 6150386
    [No Abstract]   [Full Text] [Related]  

  • 5. Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
    Alván G; Grind M; Graffner C; Sjöqvist F
    Clin Pharmacol Ther; 1984 Oct; 36(4):515-9. PubMed ID: 6478737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population.
    Du YL; Lou YQ
    Zhongguo Yao Li Xue Bao; 1990 Jan; 11(1):7-10. PubMed ID: 2403020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Debrisoquine hydroxylation polymorphism and personality.
    Bertilsson L; Alm C; De Las Carreras C; Widen J; Edman G; Schalling D
    Lancet; 1989 Mar; 1(8637):555. PubMed ID: 2564084
    [No Abstract]   [Full Text] [Related]  

  • 8. Diazepam treatment does not influence the debrisoquine or mephenytoin hydroxylation phenotyping tests.
    Spina E; Buemi AL; Sanz E; Bertilsson L
    Ther Drug Monit; 1989 Nov; 11(6):721-3. PubMed ID: 2595755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism.
    Küpfer A; Schmid B; Preisig R; Pfaff G
    Lancet; 1984 Sep; 2(8401):517-8. PubMed ID: 6147572
    [No Abstract]   [Full Text] [Related]  

  • 10. Prediction of subclinical perhexiline neuropathy in a patient with inborn error of debrisoquine hydroxylation.
    Shah RR; Oates NS; Idle JR; Smith RL; Lockhart JD
    Am Heart J; 1983 Jan; 105(1):159-61. PubMed ID: 6295127
    [No Abstract]   [Full Text] [Related]  

  • 11. Discovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development.
    Gleiter CH; Aichele G; Nilsson E; Hengen N; Antonin KH; Bieck PR
    Br J Clin Pharmacol; 1985 Jul; 20(1):81-4. PubMed ID: 4027140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmocogenetic implications of polymorphic debrisoquine hydroxylations.
    Rawlins MD
    Q J Med; 1985 Feb; 54(214):115-6. PubMed ID: 3983355
    [No Abstract]   [Full Text] [Related]  

  • 13. Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa.
    Sommers DK; Moncrieff J; Avenant J
    Hum Toxicol; 1988 May; 7(3):273-6. PubMed ID: 3391625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Debrisoquine hydroxylation phenotypes in healthy volunteers.
    Llerena A; Cobaleda J; Benítez J
    Lancet; 1989 Jun; 1(8651):1398. PubMed ID: 2567421
    [No Abstract]   [Full Text] [Related]  

  • 15. [A survey of debrisoquin hydroxylation polymorphism].
    Gachályi B; Róna K; Vas A; Káldor A
    Orv Hetil; 1986 Sep; 127(38):2299-301. PubMed ID: 3774317
    [No Abstract]   [Full Text] [Related]  

  • 16. The metabolism of debrisoquine in man: (1) regioselectivity of hydroxylation and (2) aberrant oxidative metabolism in two sibling patients with carbimazole-induced agranulocytosis.
    Ritchie JC; Crothers MJ; Shah RR; Idle JR; Smith RL
    Xenobiotica; 1986 May; 16(5):503-9. PubMed ID: 3739370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications.
    Bertilsson L; Mellström B; Sjökvist F; Mårtenson B; Asberg M
    Lancet; 1981 Mar; 1(8219):560-1. PubMed ID: 6111662
    [No Abstract]   [Full Text] [Related]  

  • 18. Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese.
    Yue QY; Bertilsson L; Dahl-Puustinen ML; Säwe J; Sjöqvist F; Johansson I; Ingelman-Sundberg M
    Lancet; 1989 Oct; 2(8667):870. PubMed ID: 2571799
    [No Abstract]   [Full Text] [Related]  

  • 19. Urinary bile acid and bile alcohol excretion does not reflect the genetic polymorphism of debrisoquine hydroxylation.
    Karlaganis G; Küpfer A; Preisig R
    Br J Clin Pharmacol; 1984 Apr; 17(4):470-3. PubMed ID: 6721994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interethnic dissociation between debrisoquine and desipramine hydroxylation.
    Rudorfer MV; Lane EA; Potter WZ
    J Clin Psychopharmacol; 1985 Apr; 5(2):89-92. PubMed ID: 3988975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.